Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus FLURBIPROFEN SODIUM.
ANSAID vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID